Leo Pharma Sues Perrigo Israel Over Generic Taclonex

Law360, New York (February 16, 2011, 5:18 PM EST) -- Leo Pharma A/S has sued generic-drug maker Perrigo Israel Pharmaceuticals Ltd. to block it from selling its own version of the Danish company's Taclonex ointment, used to treat the skin disease psoriasis vulgaris.

Leo Pharma filed the suit Monday in the U.S. District Court for the Southern District of New York, alleging that Perrigo violated its patent when the generics maker filed an abbreviated new drug application for generic Taclonex with the U.S. Food and Drug Administration.

Perrigo had sent Leo Pharma a letter in December...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.